{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:21:17Z","timestamp":1783621277107,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Clinical Medicine Discipline Team Building Project of the First Affiliated Hospital of Dali University","award":["DFYYB2024026"],"award-info":[{"award-number":["DFYYB2024026"]}]},{"name":"he Open Project of Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D","award":["AG2024002"],"award-info":[{"award-number":["AG2024002"]}]},{"name":"the General Project of the Joint Special Project of Local Universities in Yunnan Province","award":["202001BA070001-064, 202101BA070001-102"],"award-info":[{"award-number":["202001BA070001-064, 202101BA070001-102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Multiple myeloma (MM), being the second-most frequently occurring hematologic malignancy, is comprehensively assessed for its global disease burden and risk factors using the Global Burden of Disease (GBD) database and Mendelian Randomization (MR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This research utilized data from the GBD 2021 database to extensively investigate age-standardized incidence rates, mortality rates, as well as Disability - Adjusted Life Years (DALYs) linked to MM. We evaluated the impact of various geographical areas, age brackets, genders, risk factors, and Socio-Demographic Index (SDI) on the disease burden of MM. Additionally, Joinpoint regression was employed by us to analyze the temporal trends of this burden. We integrated GBD data with a two-sample MR method for causal inference to further investigate causal relationships between risk factors and MM. Finally, we applied Bayesian-Age-Period-Cohort (BAPC) models to predict future trends in MM\u2019s disease burden by using GBD data as a foundation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, the global incidence of MM was 148,755 cases, with 116,359 deaths and a total of 2,595,595 DALYs. The global age-standardized rates of MM were 1.74 (incidence), 1.37 (mortality), and 30.00 (DALYs) per 100,000 population, with higher rates observed in high-income areas. From 1990 to 2021, the annual average percentage change (AAPC) in global MM incidence was 0.54%, mortality was 0.20%, and DALYs was 0.18%. The MM burden associated with high BMI was concentrated within high-income areas such as those in Australasia and North America, while South Asia and Southeast Asia exhibited the lowest proportional burden. To further validate the causal link between BMI and MM, we conducted a two-sample MR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Over 30 years, the worldwide burden of MM has shown a significant rise. High-income countries show slowing trends due to improved healthcare, while low\/middle-income regions face rising burdens from underdiagnosis and limited access. We demonstrate a positive association between elevated BMI and increased MM risk by using MR, underscoring the imperative for obesity control in high-income nations to alleviate the MM disease burden. This study offers a basis for optimizing global health policies, improving early diagnosis, and resource allocation against the ongoing threat of MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00377-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:53:12Z","timestamp":1783615992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global burden of multiple myeloma(1990\u20132021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization"],"prefix":"10.1186","volume":"38","author":[{"given":"Run","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"9","key":"377_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56(9):1878\u201389.","journal-title":"Nat Genet"},{"issue":"6","key":"377_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"issue":"1","key":"377_CR3","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","volume":"5","author":"A Miranda-Filho","year":"2018","unstructured":"Miranda-Filho A, Pineros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1):e14\u201324.","journal-title":"Lancet Haematol"},{"issue":"1","key":"377_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines(R) Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8\u201319.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10272","key":"377_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"5","key":"377_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/bjh.12935","volume":"166","author":"LR Teras","year":"2014","unstructured":"Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014;166(5):667\u201376.","journal-title":"Br J Haematol"},{"issue":"11","key":"377_CR7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ejca.2011.01.020","volume":"47","author":"A Wallin","year":"2011","unstructured":"Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011;47(11):1606\u201315.","journal-title":"Eur J Cancer"},{"issue":"10440","key":"377_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence. prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361.","journal-title":"Lancet"},{"key":"377_CR9","doi-asserted-by":"publisher","first-page":"29034","DOI":"10.3402\/gha.v8.29034","volume":"8","author":"AR Hosseinpoor","year":"2015","unstructured":"Hosseinpoor AR, Bergen N, Schlotheuber A. Promoting health equity: WHO health inequality monitoring at global and national levels. Glob Health Action. 2015;8:29034.","journal-title":"Glob Health Action"},{"issue":"1","key":"377_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"377_CR11","first-page":"2095","volume":"50","author":"A Nahvijou","year":"2021","unstructured":"Nahvijou A. Disability-Adjusted Life Years (DALY) for Cancers in Iran, 1990 to 2016: Review of Findings from the Global Burden of Disease Study. Iran J Public Health. 2021;50(10):2095\u2013104.","journal-title":"Iran J Public Health"},{"issue":"10440","key":"377_CR12","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Global burden of","year":"2024","unstructured":"Global burden of. 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"key":"377_CR13","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.1016\/j.eclinm.2024.102873","volume":"77","author":"Z Bai","year":"2024","unstructured":"Bai Z, Han J, An J, Wang H, Du X, Yang Z, et al. The global, regional, and national patterns of change in the burden of congenital birth defects, 1990\u20132021: an analysis of the global burden of disease study 2021 and forecast to 2040. EClinicalMedicine. 2024;77:102873.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"377_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335\u201351.","journal-title":"Stat Med"},{"issue":"10053","key":"377_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","volume":"388","author":"Global","year":"2016","unstructured":"Global. regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603\u201358.","journal-title":"Lancet"},{"issue":"1","key":"377_CR16","first-page":"31","volume":"11","author":"BF Hankey","year":"2000","unstructured":"Hankey BF, Ries LA, Kosary CL, Feuer EJ, Merrill RM, Clegg LX, et al. Partitioning linear trends in age-adjusted rates. Cancer Causes Control. 2000;11(1):31\u20135.","journal-title":"Cancer Causes Control"},{"issue":"12","key":"377_CR17","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1002\/cam4.2477","volume":"8","author":"Z Liu","year":"2019","unstructured":"Liu Z, Mao X, Jiang Y, Cai N, Jin L, Zhang T, et al. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med. 2019;8(12):5787\u201399.","journal-title":"Cancer Med"},{"issue":"1","key":"377_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21147\/j.issn.1000-9604.2021.01.02","volume":"33","author":"T Zhang","year":"2021","unstructured":"Zhang T, Chen H, Yin X, He Q, Man J, Yang X, et al. Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: Findings from Global Burden of Disease Study. Chin J Cancer Res. 2021;33(1):11\u201326.","journal-title":"Chin J Cancer Res"},{"key":"377_CR19","doi-asserted-by":"publisher","first-page":"155366","DOI":"10.1016\/j.scitotenv.2022.155366","volume":"834","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yin X, Chen H, Li Y, Chen J, Yang X. Global magnitude and temporal trends of idiopathic developmental intellectual disability attributable to lead exposure from 1990 to 2019: Results from Global Burden of Disease Study. Sci Total Environ. 2022;834:155366.","journal-title":"Sci Total Environ"},{"key":"377_CR20","doi-asserted-by":"publisher","first-page":"102713","DOI":"10.1016\/j.eclinm.2024.102713","volume":"74","author":"P Sun","year":"2024","unstructured":"Sun P, Yu C, Yin L, Chen Y, Sun Z, Zhang T, et al. Global, regional, and national burden of female cancers in women of child-bearing age, 1990\u20132021: analysis of data from the global burden of disease study 2021. EClinicalMedicine. 2024;74:102713.","journal-title":"EClinicalMedicine"},{"key":"377_CR21","doi-asserted-by":"publisher","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","volume":"611","author":"X Dou","year":"2025","unstructured":"Dou X, Duan G, Zhong Y, Liu Y, Peng N, Wen L, et al. The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050. Cancer Lett. 2025;611:217440.","journal-title":"Cancer Lett"},{"issue":"20","key":"377_CR22","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","volume":"27","author":"L Yengo","year":"2018","unstructured":"Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of genome-wide association studies for height and body mass index in \u223c700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641\u20139.","journal-title":"Hum Mol Genet"},{"key":"377_CR23","doi-asserted-by":"crossref","unstructured":"Birney E. Mendelian Randomization. Cold Spring Harb Perspect Med. 2022;12(4):a041302.","DOI":"10.1101\/cshperspect.a041302"},{"issue":"3","key":"377_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/bimj.201500263","volume":"59","author":"A Riebler","year":"2017","unstructured":"Riebler A, Held L. Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biom J. 2017;59(3):531\u201349.","journal-title":"Biom J"},{"issue":"26","key":"377_CR25","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1002\/sim.6248","volume":"33","author":"V Jurgens","year":"2014","unstructured":"Jurgens V, Ess S, Cerny T, Vounatsou P. A Bayesian generalized age-period-cohort power model for cancer projections. Stat Med. 2014;33(26):4627\u201336.","journal-title":"Stat Med"},{"issue":"4","key":"377_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"10","author":"J Bowden","year":"2019","unstructured":"Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. Res Synth Methods. 2019;10(4):486\u201396.","journal-title":"Res Synth Methods"},{"issue":"7","key":"377_CR27","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-15-2406","volume":"76","author":"JN Hofmann","year":"2016","unstructured":"Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D, et al. Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Res. 2016;76(7):1935\u201341.","journal-title":"Cancer Res"},{"issue":"4","key":"377_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1210\/er.2011-1015","volume":"33","author":"M Dalamaga","year":"2012","unstructured":"Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547\u201394.","journal-title":"Endocr Rev"},{"issue":"9","key":"377_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. Jama Oncol. 2018;4(9):1221\u20137.","journal-title":"Jama Oncol"},{"issue":"1","key":"377_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1745-6673-7-25","volume":"7","author":"C Perrotta","year":"2012","unstructured":"Perrotta C, Staines A, Codd M, Kleefeld S, Crowley D, T\u2019, MA, et al. Multiple Myeloma and lifetime occupation: results from the EPILYMPH study. J Occup Med Toxicol. 2012;7(1):25.","journal-title":"J Occup Med Toxicol"},{"key":"377_CR31","doi-asserted-by":"publisher","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018. https:\/\/doi.org\/10.1111\/ejh.13083.","DOI":"10.1111\/ejh.13083"},{"key":"377_CR32","doi-asserted-by":"crossref","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1):3.","DOI":"10.3390\/medsci9010003"},{"issue":"10","key":"377_CR33","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41416-022-01704-x","volume":"126","author":"E di Martino","year":"2022","unstructured":"di Martino E, Smith L, Bradley SH, Hemphill S, Wright J, Renzi C, et al. Incidence trends for twelve cancers in younger adults-a rapid review. Br J Cancer. 2022;126(10):1374\u201386.","journal-title":"Br J Cancer"},{"issue":"7","key":"377_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","volume":"23","author":"DY Chang-Chan","year":"2021","unstructured":"Chang-Chan DY, R\u00edos-Tamayo R, Rodr\u00edguez BM, Redondo-S\u00e1nchez D, Gonz\u00e1lez Y, Marcos-Gragera R, et al. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol. 2021;23(7):1429\u201339.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"377_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"377_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria V, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"377_CR37","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DR, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137.","journal-title":"Lancet Haematol"},{"issue":"9","key":"377_CR38","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis DS, Meckl A, Hinke A, Durie B. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020;25(9):e1406\u201313.","journal-title":"Oncologist"},{"issue":"5","key":"377_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","volume":"11","author":"AS Tsao","year":"2016","unstructured":"Tsao AS, Scagliotti GV, Bunn PJ, Carbone DP, Warren GW, Bai C, et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613\u201338.","journal-title":"J Thorac Oncol"},{"key":"377_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2017.05.023","volume":"260","author":"L Wu","year":"2017","unstructured":"Wu L, Leng D, Cun D, Foged C, Yang M. Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. J Control Release. 2017;260:78\u201391.","journal-title":"J Control Release"},{"issue":"10136","key":"377_CR41","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(18)30994-2","volume":"391","author":"Measuring performance on the Healthcare Access","year":"2018","unstructured":"Measuring performance on the Healthcare Access. and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391(10136):2236\u201371.","journal-title":"Lancet"},{"issue":"3","key":"377_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4065\/mcp.2009.0426","volume":"82","author":"I Turesson","year":"2010","unstructured":"Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010;85(3):225\u201330.","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"377_CR43","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758\u201365.","journal-title":"J Clin Oncol"},{"issue":"5","key":"377_CR44","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516\u201320.","journal-title":"Blood"},{"issue":"1","key":"377_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","volume":"46","author":"M Schaapveld","year":"2010","unstructured":"Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160\u20139.","journal-title":"Eur J Cancer"},{"issue":"24","key":"377_CR46","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014;32(24):2531\u201340.","journal-title":"J Clin Oncol"},{"issue":"6","key":"377_CR47","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980\u20137.","journal-title":"Haematologica"},{"issue":"1","key":"377_CR48","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1186\/s12889-023-16677-6","volume":"23","author":"N Sandstrom","year":"2023","unstructured":"Sandstrom N, Johansson M, Jekunen A, Andersen H. Socioeconomic status and lifestyle patterns in the most common cancer types-community-based research. BMC Public Health. 2023;23(1):1722.","journal-title":"BMC Public Health"},{"key":"377_CR49","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/1471-2458-14-716","volume":"14","author":"DW Stewart","year":"2014","unstructured":"Stewart DW, Cano MA, Correa-Fernandez V, Spears CA, Li Y, Waters AJ, et al. Lower health literacy predicts smoking relapse among racially\/ethnically diverse smokers with low socioeconomic status. BMC Public Health. 2014;14:716.","journal-title":"BMC Public Health"},{"issue":"12","key":"377_CR50","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.1634\/theoncologist.2019-0057","volume":"24","author":"NR Brand","year":"2019","unstructured":"Brand NR, Qu LG, Chao A, Ilbawi AM. Delays and Barriers to Cancer Care in Low- and Middle-Income Countries: A Systematic Review. Oncologist. 2019;24(12):e1371\u201380.","journal-title":"Oncologist"},{"key":"377_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","volume":"92","author":"A Tentolouris","year":"2023","unstructured":"Tentolouris A, Ntanasis-Stathopoulos I, Terpos E. Obesity and multiple myeloma: Emerging mechanisms and perspectives. Semin Cancer Biol. 2023;92:45\u201360.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"377_CR52","doi-asserted-by":"publisher","first-page":"e75437","DOI":"10.1136\/bmjopen-2023-075437","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Han F, Liu N, Feng X, Sun X, Chi Y, et al. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019. Bmj Open. 2023;13(10):e75437.","journal-title":"Bmj Open"},{"key":"377_CR53","doi-asserted-by":"publisher","first-page":"155744","DOI":"10.1016\/j.metabol.2023.155744","volume":"152","author":"D Tan","year":"2024","unstructured":"Tan D, Ng CH, Muthiah M, Yong JN, Chee D, Teng M, et al. Rising global burden of cancer attributable to high BMI from 2010 to 2019. Metabolism. 2024;152:155744.","journal-title":"Metabolism"},{"issue":"1","key":"377_CR54","doi-asserted-by":"publisher","first-page":"20338","DOI":"10.1038\/s41598-023-46702-y","volume":"13","author":"SA Nejadghaderi","year":"2023","unstructured":"Nejadghaderi SA, Grieger JA, Karamzad N, Kolahi AA, Sullman M, Safiri S, et al. Burden of diseases attributable to excess body weight in the Middle East and North Africa region, 1990\u20132019. Sci Rep. 2023;13(1):20338.","journal-title":"Sci Rep"},{"key":"377_CR55","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.7189\/jogh.14.04200","volume":"14","author":"P Wang","year":"2024","unstructured":"Wang P, Huang S, Wang R, Shi X, Xu H, Peng J, et al. Global burden and cross-country inequalities in diseases associated with high body mass index from 1990 to 2019: Result from the Global Burden of Disease Study 2019. J Glob Health. 2024;14:4200.","journal-title":"J Glob Health"},{"key":"377_CR56","doi-asserted-by":"crossref","unstructured":"Di Renzo L, Gualtieri P, De Lorenzo A. Diet, nutrition and chronic degenerative diseases. Nutrients. 2021;13(4):1372.","DOI":"10.3390\/nu13041372"},{"issue":"11","key":"377_CR57","doi-asserted-by":"publisher","first-page":"e70039","DOI":"10.1002\/hem3.70039","volume":"8","author":"W Bruins","year":"2024","unstructured":"Bruins W, Rentenaar R, Newcomb J, Zheng W, Ruiter R, Baardemans T, et al. Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma. Hemasphere. 2024;8(11):e70039.","journal-title":"Hemasphere"},{"issue":"12","key":"377_CR58","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1021\/acs.bioconjchem.4c00497","volume":"35","author":"Q Yang","year":"2024","unstructured":"Yang Q, Song L, Chen Z, Qiu Y, Wang T, Sun X, et al. Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted (68)Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study. Bioconjug Chem. 2024;35(12):1985\u201396.","journal-title":"Bioconjug Chem"},{"key":"377_CR59","doi-asserted-by":"publisher","first-page":"1436587","DOI":"10.3389\/fonc.2024.1436587","volume":"14","author":"P Sesques","year":"2024","unstructured":"Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, et al. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy. Front Oncol. 2024;14:1436587.","journal-title":"Front Oncol"},{"issue":"8","key":"377_CR60","first-page":"e66225","volume":"16","author":"S Agrawal","year":"2024","unstructured":"Agrawal S, Vagha S. A Comprehensive Review of Artificial Intelligence in Prostate Cancer Care: State-of-the-Art Diagnostic Tools and Future Outlook. Cureus. 2024;16(8):e66225.","journal-title":"Cureus"},{"issue":"6","key":"377_CR61","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1365-2141.2011.08742.x","volume":"154","author":"DJ Weatherall","year":"2011","unstructured":"Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154(6):736\u201344.","journal-title":"Br J Haematol"},{"issue":"5","key":"377_CR62","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1365-2141.2010.08131.x","volume":"149","author":"R Colah","year":"2010","unstructured":"Colah R, Gorakshakar A, Phanasgaonkar S, D\u2019Souza E, Nadkarni A, Surve R, et al. Epidemiology of beta-thalassaemia in Western India: mapping the frequencies and mutations in sub-regions of Maharashtra and Gujarat. Br J Haematol. 2010;149(5):739\u201347.","journal-title":"Br J Haematol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00377-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00377-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00377-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:02:16Z","timestamp":1783620136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00377-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00377-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data utilized in this study were obtained from the publicly available \u201cGlobal Burden of Disease Study 2021\u201d (GBD 2021). As this research does not involve human participants or animal experimentation, no further ethical approval is necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study does not require additional publication permission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}